公开(公告)号：EP2316459A1

公开(公告)日：2011-05-04

申请号：EP10010732.5

申请日：2003-07-29

申请人： Rigel Pharmaceuticals, Inc.

发明人： Singh, Rajinder ,  Argade, Ankush ,  Payan, Donald G. ,  Clough, Jeffrey ,  Keim, Holger ,  Sylvain, Catherine ,  Li, Hui ,  Bhamidipati, Somasekhar

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61P35/00 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮和/或其相关症状和多发性硬化症和/或其相关症状。

公开(公告)号：EP2130541A3

公开(公告)日：2013-12-18

申请号：EP09004539.4

申请日：2003-07-29

申请人： Rigel Pharmaceuticals, Inc.

发明人： Singh, Rajinder ,  Argade, Ankush ,  Payan, Donald G. ,  Clough, Jeffrey ,  Keim, Holger ,  Sylvain, Catherine ,  Li, Hui ,  Bhamidipati, Somasekhar

IPC分类号： A61K31/505 ,  C07D239/28 ,  A61P37/08 ,  A61K31/506 ,  A61K31/519 ,  C07D403/12 ,  C07D413/14 ,  C07D401/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D471/04 ,  C07D498/04

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

公开(公告)号：EP2316459B1

公开(公告)日：2013-11-06

申请号：EP10010732.5

申请日：2003-07-29

申请人： Rigel Pharmaceuticals, Inc.

发明人： Singh, Rajinder ,  Argade, Ankush ,  Payan, Donald G. ,  Clough, Jeffrey ,  Keim, Holger ,  Sylvain, Catherine ,  Li, Hui ,  Bhamidipati, Somasekhar

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61P35/00 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

公开(公告)号：EP2130541A2

公开(公告)日：2009-12-09

申请号：EP09004539.4

申请日：2003-07-29

申请人： Rigel Pharmaceuticals, Inc.

发明人： Singh, Rajinder ,  Argade, Ankush ,  Payan, Donald G. ,  Clough, Jeffrey ,  Keim, Holger ,  Sylvain, Catherine ,  Li, Hui ,  Bhamidipati, Somasekhar

IPC分类号： A61K31/505 ,  C07D239/28 ,  A61P37/08

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供治疗或与2,4-嘧啶二胺化合物，以及治疗，预防或改善与寻求疾病相关的症状的方法预防自身免疫性疾病的方法。 自身免疫性疾病的具体例子，也可以治疗或预防的化合物包括类风湿性关节炎和/或其相关症状，全身红斑狼疮迪基和/或其相关症状和多发性硬化和/或其相关症状。

公开(公告)号：EP2281563B1

公开(公告)日：2013-09-18

申请号：EP10011119.4

申请日：2003-01-31

申请人： Rigel Pharmaceuticals, Inc.

发明人： Singh, Rajinder ,  Argade, Ankush ,  Payan, Donald G. ,  Molineaux, Susan ,  Holland, Sacha J. ,  Clough, Jeffrey ,  Keim, Holger ,  Bhamidipati, Somasekhar ,  Sylvain, Catherine ,  Li, Hui ,  Rossi, Alexander B.

IPC分类号： A61K31/505 ,  C07D239/28 ,  A61P37/08

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5395 ,  A61K31/551 ,  A61K45/06 ,  C07D239/48 ,  C07D265/36 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14 ,  C07F5/027

摘要： The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signalling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signalling cascades.

公开(公告)号：EP2281563A1

公开(公告)日：2011-02-09

申请号：EP10011119.4

申请日：2003-01-31

申请人： Rigel Pharmaceuticals, Inc.

发明人： Singh, Rajinder ,  Argade, Ankush ,  Payan, Donald G. ,  Molineaux, Susan ,  Holland, Sacha J. ,  Clough, Jeffrey ,  Keim, Holger ,  Bhamidipati, Somasekhar ,  Sylvain, Catherine ,  Li, Hui ,  Rossi, Alexander B.

IPC分类号： A61K31/505 ,  C07D239/28 ,  A61P37/08

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5395 ,  A61K31/551 ,  A61K45/06 ,  C07D239/48 ,  C07D265/36 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14 ,  C07F5/027

摘要： The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signalling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signalling cascades.

摘要翻译： 本发明提供了抑制导致释放化学介质，中间体和合成化合物的方法的IgE和/或IgG受体信号级联的2,4-嘧啶二胺化合物和在多种情况下使用化合物的方法，包括 在治疗和预防由IgE和/或IgG受体信号传导级联的激活所引起的由脱颗粒和其它过程释放化学介质引起或与之相关的疾病。